Chao Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chao Zhu has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Anneke van der Walt
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia
12 shared publications - Tomas Kalincik
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
12 shared publications Helmut Butzkueven
Affiliations Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia, Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia
8 shared publicationsSerkan Ozakbas
Dokuz Eylul University, Izmir, Turkey
8 shared publicationsDana Horakova
Charles University in Prague and General University Hospital, Prague, Czech Republic
7 shared publications- Helmut Butzkueven
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia
7 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (9) , e0001722
Strategies for integrating artificial intelligence and cognitive assessment to predict disability progression in relapsing-remitting multiple sclerosis: A model development study
Serial cognitive assessment in multiple sclerosis can help identify patients at higher risk of disability progression, but high dimensionality of reaction-time data makes analysis challenging. We developed a method to convert longitudinal reaction-time data into images and applied deep survival modelling to predict disability progression in relapsing-remitting MS (RRMS). In this cohort study, clinical data were obtained from the MSBase registry and cognitive data from the MSReactor computerised cognitive battery between February 2016 and September 2022, with a median follow-up of 3.2 years. The serial reaction-time data from three tasks (psychomotor function [R], attention [G], and working memory [B]) were converted into multicolour images using RGB encoding. We extracted the key features from the images using a convolutional neural network and combined them with clinical variables in a Transformer-based survival model (MS-TranSurv) to predict time to confirmed disability progression. Discrimination, calibration, and accuracy were assessed using the C-index, integrated Brier score (iBS), and time-dependent area under the receiver operating characteristic (tAUROC). Performance was compared with other machine learning models, including Dynamic DeepHit, Recurrent Deep Survival Machines, a Cox proportional hazards model in traditional statistics using clinical variables only, and a version of MS-TransSurv using mean test values. A total of 746 RRMS patients were included. MS-TranSurv showed slightly higher discrimination compared with benchmark models, with a C-index of 0.61 (95% CI 0.54–0.68) and tAUROC of 0.74 (95% CI 0.63–0.85), as well as comparable calibration, with an iBS of 0.24 (95% CI 0.16–0.32). Using individual test-level data provided slightly better performance than using summary measures. Longitudinal cognitive reaction-time data can be used for survival-based prediction of disability progression in RRMS. This framework supports remote cognitive monitoring and may improve risk stratification and clinical trial enrichment, with potential applicability to other high-dimensional digital biomarkers.
- 25 September 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (9) , e0001722
Open AccessStrategies for integrating artificial intelligence and cognitive assessment to predict disability progression in relapsing-remitting multiple sclerosis: A model development study
Serial cognitive assessment in multiple sclerosis can help identify patients at higher risk of disability progression, but high dimensionality of reaction-time data makes analysis challenging. We developed a method to convert longitudinal reaction-time data into images and applied deep survival modelling to predict disability progression in relapsing-remitting MS (RRMS). In this cohort study, clinical data were obtained from the MSBase registry and cognitive data from the MSReactor computerised cognitive battery between February 2016 and September 2022, with a median follow-up of 3.2 years. The serial reaction-time data from three tasks (psychomotor function [R], attention [G], and working memory [B]) were converted into multicolour images using RGB encoding. We extracted the key features from the images using a convolutional neural network and combined them with clinical variables in a Transformer-based survival model (MS-TranSurv) to predict time to confirmed disability progression. Discrimination, calibration, and accuracy were assessed using the C-index, integrated Brier score (iBS), and time-dependent area under the receiver operating characteristic (tAUROC). Performance was compared with other machine learning models, including Dynamic DeepHit, Recurrent Deep Survival Machines, a Cox proportional hazards model in traditional statistics using clinical variables only, and a version of MS-TransSurv using mean test values. A total of 746 RRMS patients were included. MS-TranSurv showed slightly higher discrimination compared with benchmark models, with a C-index of 0.61 (95% CI 0.54–0.68) and tAUROC of 0.74 (95% CI 0.63–0.85), as well as comparable calibration, with an iBS of 0.24 (95% CI 0.16–0.32). Using individual test-level data provided slightly better performance than using summary measures. Longitudinal cognitive reaction-time data can be used for survival-based prediction of disability progression in RRMS. This framework supports remote cognitive monitoring and may improve risk stratification and clinical trial enrichment, with potential applicability to other high-dimensional digital biomarkers.
- 14 August 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (11) , 982-991
Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data
Background Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice. Methods We conducted an observational cohort study emulating a target trial using data from the MSBase and Observatoire Français de la Sclérose en Plaques registries (January 2021 to December 2024). Adults with RRMS initiating ofatumumab or ocrelizumab were included. Patients were matched 1:1 using propensity scores. Primary outcomes were annualised relapse rate (ARR) and time to first relapse. Secondary outcomes included time to confirmed disability progression (CDP), progression independent of relapse activity (PIRA), confirmed disability improvement (CDI), MRI activity and treatment discontinuation. Negative binomial and Cox regression models were applied. Results A total of 5288 patients were matched with a median follow-up of 1.2 years for ofatumumab and 1.4 years for ocrelizumab. ARR was 0.07 (95% CI 0.05 to 0.08) with ofatumumab and 0.04 (0.03 to 0.05) with ocrelizumab, corresponding to an ARR ratio of 1.75 (1.43 to 2.13). Ofatumumab was associated with a lower risk of CDP (HR 0.66; 0.49 to 0.87) and PIRA (0.53; 0.39 to 0.73), but a lower probability of CDI (0.76; 0.60 to 0.96). No significant differences were observed in MRI activity or treatment discontinuation. Conclusions Both therapies were highly effective in a large cohort of patients with RRMS, with very low relapse or CDP rates. Ofatumumab was associated with slightly greater disability control, while ocrelizumab more effectively suppressed relapses. These differences were modest, and their clinical relevance requires further evidence and should be interpreted with caution.
- 14 August 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (11) , 982-991
Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data
Background Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice. Methods We conducted an observational cohort study emulating a target trial using data from the MSBase and Observatoire Français de la Sclérose en Plaques registries (January 2021 to December 2024). Adults with RRMS initiating ofatumumab or ocrelizumab were included. Patients were matched 1:1 using propensity scores. Primary outcomes were annualised relapse rate (ARR) and time to first relapse. Secondary outcomes included time to confirmed disability progression (CDP), progression independent of relapse activity (PIRA), confirmed disability improvement (CDI), MRI activity and treatment discontinuation. Negative binomial and Cox regression models were applied. Results A total of 5288 patients were matched with a median follow-up of 1.2 years for ofatumumab and 1.4 years for ocrelizumab. ARR was 0.07 (95% CI 0.05 to 0.08) with ofatumumab and 0.04 (0.03 to 0.05) with ocrelizumab, corresponding to an ARR ratio of 1.75 (1.43 to 2.13). Ofatumumab was associated with a lower risk of CDP (HR 0.66; 0.49 to 0.87) and PIRA (0.53; 0.39 to 0.73), but a lower probability of CDI (0.76; 0.60 to 0.96). No significant differences were observed in MRI activity or treatment discontinuation. Conclusions Both therapies were highly effective in a large cohort of patients with RRMS, with very low relapse or CDP rates. Ofatumumab was associated with slightly greater disability control, while ocrelizumab more effectively suppressed relapses. These differences were modest, and their clinical relevance requires further evidence and should be interpreted with caution.
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (8) , e013687
Identifying Risk-De-Escalating Markers in PREVENT-Defined Intermediate-Risk Older Adults: Insights From ASPREE
BACKGROUND: Previous studies showed that the Pooled Cohort Equations substantially overestimate atherosclerotic cardiovascular disease (ASCVD) risk in older adults, and the recently published predicting risk of cardiovascular disease events (PREVENT) equation offers better performance. Identifying markers that can further refine risk estimates is essential for personalized prevention in this age group. This study evaluates the clinical utility of 6 markers for reclassifying intermediate-risk older adults (10-year PREVENT-estimated ASCVD risk, 7.5% to 20%), with a focus on de-escalation. METHODS: This post hoc analysis evaluated intermediate-risk older adults aged ≥70 years using data from ASPREE (Aspirin in Reducing Events in the Elderly; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583). ASPREE was a randomized trial of low-dose aspirin versus placebo in healthy older adults who were free of prior cardiovascular events at enrollment. Six markers were evaluated: the lowest quartile (Q1) of NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-TnI (high-sensitivity troponin I), and hs-CRP (high-sensitivity C-reactive protein), polygenic risk for lipoprotein(a) and polygenic risk for coronary artery disease, and absence of family history of ASCVD. Incident ASCVD events were adjudicated by expert panels. Statistical performance of each marker was assessed using diagnostic likelihood ratios, change in Harrell C statistic (ΔC), and net reclassification index relative to a baseline model incorporating variables included in the PREVENT equation. RESULTS: The study included 7764 participants (48% female; median age, 74 years [interquartile range, 72–77]), with a median follow-up of 10.3 years. During follow-up, 725 participants (9.3%) experienced ASCVD events. Q1 polygenic risk for coronary artery disease was the most powerful marker for down-grading risk, providing 37% risk reduction (diagnostic likelihood ratio: 0.627) and improving discrimination (ΔC: +1.44%; P =0.004) when compared with the baseline model, and correctly reclassifying 25.9% of nonevents downward (net reclassification index: 0.101). Q1 hs-TnI showed second-best performance (diagnostic likelihood ratio: 0.727; ΔC: +0.71%, net reclassification index: 0.075). CONCLUSIONS: Adding polygenic risk for coronary artery disease to the PREVENT equations may further personalize risk estimates and support clinical decision-making for older adults at intermediate risk for ASCVD events.
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (8) , e013687
Identifying Risk-De-Escalating Markers in PREVENT-Defined Intermediate-Risk Older Adults: Insights From ASPREE
BACKGROUND: Previous studies showed that the Pooled Cohort Equations substantially overestimate atherosclerotic cardiovascular disease (ASCVD) risk in older adults, and the recently published predicting risk of cardiovascular disease events (PREVENT) equation offers better performance. Identifying markers that can further refine risk estimates is essential for personalized prevention in this age group. This study evaluates the clinical utility of 6 markers for reclassifying intermediate-risk older adults (10-year PREVENT-estimated ASCVD risk, 7.5% to 20%), with a focus on de-escalation. METHODS: This post hoc analysis evaluated intermediate-risk older adults aged ≥70 years using data from ASPREE (Aspirin in Reducing Events in the Elderly; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583). ASPREE was a randomized trial of low-dose aspirin versus placebo in healthy older adults who were free of prior cardiovascular events at enrollment. Six markers were evaluated: the lowest quartile (Q1) of NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-TnI (high-sensitivity troponin I), and hs-CRP (high-sensitivity C-reactive protein), polygenic risk for lipoprotein(a) and polygenic risk for coronary artery disease, and absence of family history of ASCVD. Incident ASCVD events were adjudicated by expert panels. Statistical performance of each marker was assessed using diagnostic likelihood ratios, change in Harrell C statistic (ΔC), and net reclassification index relative to a baseline model incorporating variables included in the PREVENT equation. RESULTS: The study included 7764 participants (48% female; median age, 74 years [interquartile range, 72–77]), with a median follow-up of 10.3 years. During follow-up, 725 participants (9.3%) experienced ASCVD events. Q1 polygenic risk for coronary artery disease was the most powerful marker for down-grading risk, providing 37% risk reduction (diagnostic likelihood ratio: 0.627) and improving discrimination (ΔC: +1.44%; P =0.004) when compared with the baseline model, and correctly reclassifying 25.9% of nonevents downward (net reclassification index: 0.101). Q1 hs-TnI showed second-best performance (diagnostic likelihood ratio: 0.727; ΔC: +0.71%, net reclassification index: 0.075). CONCLUSIONS: Adding polygenic risk for coronary artery disease to the PREVENT equations may further personalize risk estimates and support clinical decision-making for older adults at intermediate risk for ASCVD events.
- 14 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (7) , e214707
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder
Previous studies have reported inconsistent findings regarding the impact of age at onset on relapse risk in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), although older disease onset has been linked to more rapid disability accrual. This is in contrast to multiple sclerosis, where advancing age and older onset are associated with reduced relapse activity, allowing for treatment de-escalation or discontinuation in some older patients. The aim of this study was to clarify the influence of age at onset on relapse risk as well as disability accrual in a large, international cohort of patients with NMOSD. We conducted a retrospective, multicenter cohort study using the MSBase data registry to evaluate annualized relapse rates (ARRs), time to first relapse, and time to Expanded Disability Status Scale (EDSS) scores of 4 and 6. For inclusion, a diagnosis of AQP4-IgG NMOSD according to the latest iteration of the criteria and availability of the minimum data set were required. Patients were stratified as pediatric onset (55 years of age). Analyses included patients on high-efficacy therapy (HET), those on low-efficacy therapy (LET), and an incident cohort with the first clinical visit within 12 months from disease onset. Predictors of first relapse and EDSS 4/6 thresholds were analyzed using Cox proportional models. Data from 539 patients (42 pediatric, 421 with early onset, 76 with late onset; 85.2% female) with a median age at onset of 35 years (Q1 25.10, Q3 47.60) and a disease duration of 7.42 years (Q1 3.23, Q3 13.10) were analyzed. ARR and time to first relapse were not influenced by age at disease onset. Patients on HET had fewer relapses than those on LET (p < 0.001). Older age was linked to faster disability accumulation. In addition, higher baseline EDSS scores and delayed treatment were independent predictors of future disability. Our study demonstrates that while age at onset does not affect relapse risk, older patients experience more rapid disability accrual. These findings underscore the importance of early initiation of effective preventive immunotherapy in all age groups. The primary limitations of this study pertain to its retrospective design and the sole reliance on EDSS for disability assessment.
- 14 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (7) , e214707
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder
Previous studies have reported inconsistent findings regarding the impact of age at onset on relapse risk in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), although older disease onset has been linked to more rapid disability accrual. This is in contrast to multiple sclerosis, where advancing age and older onset are associated with reduced relapse activity, allowing for treatment de-escalation or discontinuation in some older patients. The aim of this study was to clarify the influence of age at onset on relapse risk as well as disability accrual in a large, international cohort of patients with NMOSD. We conducted a retrospective, multicenter cohort study using the MSBase data registry to evaluate annualized relapse rates (ARRs), time to first relapse, and time to Expanded Disability Status Scale (EDSS) scores of 4 and 6. For inclusion, a diagnosis of AQP4-IgG NMOSD according to the latest iteration of the criteria and availability of the minimum data set were required. Patients were stratified as pediatric onset (55 years of age). Analyses included patients on high-efficacy therapy (HET), those on low-efficacy therapy (LET), and an incident cohort with the first clinical visit within 12 months from disease onset. Predictors of first relapse and EDSS 4/6 thresholds were analyzed using Cox proportional models. Data from 539 patients (42 pediatric, 421 with early onset, 76 with late onset; 85.2% female) with a median age at onset of 35 years (Q1 25.10, Q3 47.60) and a disease duration of 7.42 years (Q1 3.23, Q3 13.10) were analyzed. ARR and time to first relapse were not influenced by age at disease onset. Patients on HET had fewer relapses than those on LET (p < 0.001). Older age was linked to faster disability accumulation. In addition, higher baseline EDSS scores and delayed treatment were independent predictors of future disability. Our study demonstrates that while age at onset does not affect relapse risk, older patients experience more rapid disability accrual. These findings underscore the importance of early initiation of effective preventive immunotherapy in all age groups. The primary limitations of this study pertain to its retrospective design and the sole reliance on EDSS for disability assessment.
- Open Access
- 1 April 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (4) , 243
Cross-sectional brain volumetric measures and disability outcomes in relapsing–remitting multiple sclerosis
Background: Automated cross-sectional magnetic resonance imaging (MRI) measures of brain volume are becoming available in clinical practice; however, their prognostic utility in multiple sclerosis remains unclear. Objectives: We investigated associations between cross-sectional brain and brain lesion volume measures and subsequent disability outcomes in relapsing–remitting multiple sclerosis (RRMS). Methods: We conducted a multicentre international cohort study using data collected prospectively in the MSBase Registry. MRI analysis was performed using icobrain ms. Associations between MRI volumetric measurements and confirmed disability worsening (CDW), progression independent of relapse activity (PIRA), secondary progressive multiple sclerosis (SPMS) and confirmed disability improvement (CDI) were examined using multivariable Cox proportional hazards models. Results: A total of 1598 patients were included and 68.6% received high-efficacy disease-modifying therapy during follow-up. Normalised lateral ventricular volume (mL) was significantly associated with all disability outcomes, including PIRA (hazard ratio 1.007; 95% confidence interval 1.002 − 1.012; p = 0.009). Higher normalised whole brain, grey matter and white matter volumes were all significantly associated with a lower hazard of CDW and higher hazard of achieving CDI. Higher normalised white matter volume was also significantly associated with a lower hazard of PIRA. Higher T1-weighted black hole lesion volume was significantly associated with an increased hazard of conversion to SPMS; lesion volume measures were otherwise not significantly associated with disability outcomes. Conclusions: Automated MRI measures of brain volume from a single time point demonstrated prognostic utility in a highly treated cohort of people with RRMS. The results suggest that normalised lateral ventricular volume is a particularly informative prognostic marker across multiple disability outcomes.
- 1 April 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (4) , 243
Open AccessCross-sectional brain volumetric measures and disability outcomes in relapsing–remitting multiple sclerosis
Background: Automated cross-sectional magnetic resonance imaging (MRI) measures of brain volume are becoming available in clinical practice; however, their prognostic utility in multiple sclerosis remains unclear. Objectives: We investigated associations between cross-sectional brain and brain lesion volume measures and subsequent disability outcomes in relapsing–remitting multiple sclerosis (RRMS). Methods: We conducted a multicentre international cohort study using data collected prospectively in the MSBase Registry. MRI analysis was performed using icobrain ms. Associations between MRI volumetric measurements and confirmed disability worsening (CDW), progression independent of relapse activity (PIRA), secondary progressive multiple sclerosis (SPMS) and confirmed disability improvement (CDI) were examined using multivariable Cox proportional hazards models. Results: A total of 1598 patients were included and 68.6% received high-efficacy disease-modifying therapy during follow-up. Normalised lateral ventricular volume (mL) was significantly associated with all disability outcomes, including PIRA (hazard ratio 1.007; 95% confidence interval 1.002 − 1.012; p = 0.009). Higher normalised whole brain, grey matter and white matter volumes were all significantly associated with a lower hazard of CDW and higher hazard of achieving CDI. Higher normalised white matter volume was also significantly associated with a lower hazard of PIRA. Higher T1-weighted black hole lesion volume was significantly associated with an increased hazard of conversion to SPMS; lesion volume measures were otherwise not significantly associated with disability outcomes. Conclusions: Automated MRI measures of brain volume from a single time point demonstrated prognostic utility in a highly treated cohort of people with RRMS. The results suggest that normalised lateral ventricular volume is a particularly informative prognostic marker across multiple disability outcomes.
- 29 October 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (1) , 50-58
Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis
Introduction Late-onset multiple sclerosis (LOMS) now comprises over 10% of MS diagnoses in contemporary cohorts. The effectiveness of disease-modifying therapies (DMTs) in LOMS is unclear. We aimed to establish the comparative effectiveness of moderate–high-efficacy versus low-efficacy DMTs in LOMS. Methods Using data from the MSBase registry, this multicentre cohort study included people with MS with symptom onset after age 50. Covariates were balanced using inverse-probability-treatment-weighting (IPTW). Primary outcomes were time to first relapse and annualised relapse rate (ARR). Secondary outcomes were 6-month confirmed disability progression (CDP), confirmed disability improvement (CDI), relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA). Results Of 1032 participants, 472 received moderate–high-efficacy DMTs and 560 received low-efficacy DMTs. IPTW-weighted ARR was 0.06 for moderate–high-efficacy and 0.09 for low-efficacy DMTs, corresponding to an ARR ratio of 0.68 (95% CI 0.50 to 0.93, p=0.01). HR for time to first relapse was 0.66 (95% CI 0.47 to 0.91, p=0.01) in favour of moderate–high-efficacy DMTs. Among 856 participants with adequate follow-up, 37% experienced CDP over a median of 4.43 years, with most events (83.6%) attributable to PIRA. The HR for time to CDP was 0.78 (p=0.08) and RAW was 0.69 (p=0.31) in favour of moderate–high-efficacy DMTs, though neither reached statistical significance. There was no difference in CDI or PIRA. Conclusion Moderate–high-efficacy DMTs reduced relapse risk in LOMS. Relapse activity was low. CDP was common and driven by PIRA. Although the CDP and RAW results did not reach statistical significance, the overall findings support the initial use of moderate–high-efficacy DMTs in LOMS.
- 29 October 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (1) , 50-58
Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis
Introduction Late-onset multiple sclerosis (LOMS) now comprises over 10% of MS diagnoses in contemporary cohorts. The effectiveness of disease-modifying therapies (DMTs) in LOMS is unclear. We aimed to establish the comparative effectiveness of moderate–high-efficacy versus low-efficacy DMTs in LOMS. Methods Using data from the MSBase registry, this multicentre cohort study included people with MS with symptom onset after age 50. Covariates were balanced using inverse-probability-treatment-weighting (IPTW). Primary outcomes were time to first relapse and annualised relapse rate (ARR). Secondary outcomes were 6-month confirmed disability progression (CDP), confirmed disability improvement (CDI), relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA). Results Of 1032 participants, 472 received moderate–high-efficacy DMTs and 560 received low-efficacy DMTs. IPTW-weighted ARR was 0.06 for moderate–high-efficacy and 0.09 for low-efficacy DMTs, corresponding to an ARR ratio of 0.68 (95% CI 0.50 to 0.93, p=0.01). HR for time to first relapse was 0.66 (95% CI 0.47 to 0.91, p=0.01) in favour of moderate–high-efficacy DMTs. Among 856 participants with adequate follow-up, 37% experienced CDP over a median of 4.43 years, with most events (83.6%) attributable to PIRA. The HR for time to CDP was 0.78 (p=0.08) and RAW was 0.69 (p=0.31) in favour of moderate–high-efficacy DMTs, though neither reached statistical significance. There was no difference in CDI or PIRA. Conclusion Moderate–high-efficacy DMTs reduced relapse risk in LOMS. Relapse activity was low. CDP was common and driven by PIRA. Although the CDP and RAW results did not reach statistical significance, the overall findings support the initial use of moderate–high-efficacy DMTs in LOMS.
- Open Access
- 29 August 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54 (9)
The effect of low-dose aspirin on reversing frailty status in older prefrail and frail adults: a secondary analysis of the ASPREE randomised clinical trial
Background: Chronic low-grade inflammation is hypothesised as a central driver of frailty. This study aims to evaluate whether low-dose aspirin can reverse frailty status among initially prefrail/frail older adults. Methods: This was a post hoc subgroup analysis of the Aspirin in Reducing Events in the Elderly (ASPREE), a randomised, placebo-controlled trial, involving community-dwelling adults aged ≥65 years. The median (Interquartile range) follow-up was 4.7 (3.6–5.7) years. We included participants who were prefrail or frail at baseline, with frailty assessed using two validated measures: the Fried Frailty Phenotype (FFP) and the Deficit-Accumulation Frailty Index (FI). Frailty reversal was defined as a transition to a less severe state (from frail to prefrail/nonfrail, prefrail to nonfrail). The discrete-time survival model was used for outcome analysis; linear mixed-effects models compared longitudinal frailty trajectories between the treatment arms. Results: Among 6595 and 8766 participants included in the FFP and FI analyses, respectively, there was no significant difference in frailty status reversal between aspirin and placebo groups (FFP-HR: 1.00, 95% CI: 0.92–1.07; FI-HR: 1.00, 95% CI: 0.94–1.07). No significant difference was found in the change of FFP counts (β = 0.014, SE = 0.007, P = .06) and FI score (β = 0.0004, SE = 0.004, P = .37) between the aspirin and placebo groups over time, suggesting that aspirin neither reversed nor worsened frailty severity. Subgroup analyses revealed no effect modification by frailty risk factors such as age, sex, race and medical history. Conclusion: Low-dose aspirin has no effect in reversing frailty among prefrail and frail individuals. The findings highlight the need to explore alternative anti-inflammatory medications for frailty management.
- 29 August 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54 (9)
Open AccessThe effect of low-dose aspirin on reversing frailty status in older prefrail and frail adults: a secondary analysis of the ASPREE randomised clinical trial
Background: Chronic low-grade inflammation is hypothesised as a central driver of frailty. This study aims to evaluate whether low-dose aspirin can reverse frailty status among initially prefrail/frail older adults. Methods: This was a post hoc subgroup analysis of the Aspirin in Reducing Events in the Elderly (ASPREE), a randomised, placebo-controlled trial, involving community-dwelling adults aged ≥65 years. The median (Interquartile range) follow-up was 4.7 (3.6–5.7) years. We included participants who were prefrail or frail at baseline, with frailty assessed using two validated measures: the Fried Frailty Phenotype (FFP) and the Deficit-Accumulation Frailty Index (FI). Frailty reversal was defined as a transition to a less severe state (from frail to prefrail/nonfrail, prefrail to nonfrail). The discrete-time survival model was used for outcome analysis; linear mixed-effects models compared longitudinal frailty trajectories between the treatment arms. Results: Among 6595 and 8766 participants included in the FFP and FI analyses, respectively, there was no significant difference in frailty status reversal between aspirin and placebo groups (FFP-HR: 1.00, 95% CI: 0.92–1.07; FI-HR: 1.00, 95% CI: 0.94–1.07). No significant difference was found in the change of FFP counts (β = 0.014, SE = 0.007, P = .06) and FI score (β = 0.0004, SE = 0.004, P = .37) between the aspirin and placebo groups over time, suggesting that aspirin neither reversed nor worsened frailty severity. Subgroup analyses revealed no effect modification by frailty risk factors such as age, sex, race and medical history. Conclusion: Low-dose aspirin has no effect in reversing frailty among prefrail and frail individuals. The findings highlight the need to explore alternative anti-inflammatory medications for frailty management.
- Open Access
- 21 August 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (5)
Persistent progression independent of relapse activity in multiple sclerosis
Patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression independent of relapse activity (PIRA), which can be an early sign of secondary progressive MS (SPMS). We defined persistent PIRA as ongoing sustained disability over the entire available follow-up period. However, PIRA events can regress over time. Identifying factors that predict PIRA persistence is of great interest as they can refine the definition of RRMS to SPMS transition. Equally, factors associated with the non-persistence of PIRA have potential treatment implications for patients suffering from a PIRA event. We conducted a study to examine risk factors for PIRA persistence and risk differences in long-term disability progression between persistent and non-persistent PIRA. In this cohort study, we included only patients who had already experienced a PIRA event and investigated the persistence of disability progression following their first PIRA event. Therefore, PIRA occurrence time was set as the baseline. Data were collected from the MSBase registry between April 1995 and January 2024, with a median follow-up of 8.7 years. The primary outcome was time to 6-month confirmed non-persistence of PIRA. Secondary outcomes comprised time to 6-month confirmed Expanded Disability Status Scale (EDSS) 6 and time to SPMS. A stratified Cox regression model was used to identify risk factors associated with non-persistent PIRA. We then matched persistent PIRA patients with non-persistent PIRA patients in a 1:1 ratio using propensity scores, and compared their risk of reaching EDSS 6 using the Cox regression model. We re-matched patients with complete Kurtzke Functional Systems Scores to compare their risks of reaching SPMS. We included 4713 RRMS patients with PIRA, of whom around one-third experienced a post-PIRA disability improvement, over a relatively long period (median of 2.6 years to improvement). Use of high-efficacy disease-modifying therapies (DMT) at baseline [hazard ratio, 1.22; 95% confidence interval, (1.08–1.38); P = 0.0015], lower baseline EDSS [hazard ratio, 0.73 (0.69–0.78); P < 0.0001] and younger age [per 10 years; hazard ratio, 0.84 (0.80–0.89); P < 0.0001] were associated with non-persistent PIRA. Patients with non-persistent PIRA had a hazard ratio of 0.19 [95% confidence interval, (0.15–0.25); P < 0.0001] for reaching EDSS 6 and 0.18 [(0.11–0.29); P < 0.0001] for reaching SPMS compared to patients with persistent PIRA. PIRA events slowly regress in one-third of patients. Patients with persistent PIRA had a substantially higher risk of reaching EDSS 6 and SPMS than those with non-persistent PIRA. Younger age, lower baseline EDSS, and use of high-efficacy DMT during PIRA events were associated with PIRA regression.
- 21 August 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (5)
Open AccessPersistent progression independent of relapse activity in multiple sclerosis
Patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression independent of relapse activity (PIRA), which can be an early sign of secondary progressive MS (SPMS). We defined persistent PIRA as ongoing sustained disability over the entire available follow-up period. However, PIRA events can regress over time. Identifying factors that predict PIRA persistence is of great interest as they can refine the definition of RRMS to SPMS transition. Equally, factors associated with the non-persistence of PIRA have potential treatment implications for patients suffering from a PIRA event. We conducted a study to examine risk factors for PIRA persistence and risk differences in long-term disability progression between persistent and non-persistent PIRA. In this cohort study, we included only patients who had already experienced a PIRA event and investigated the persistence of disability progression following their first PIRA event. Therefore, PIRA occurrence time was set as the baseline. Data were collected from the MSBase registry between April 1995 and January 2024, with a median follow-up of 8.7 years. The primary outcome was time to 6-month confirmed non-persistence of PIRA. Secondary outcomes comprised time to 6-month confirmed Expanded Disability Status Scale (EDSS) 6 and time to SPMS. A stratified Cox regression model was used to identify risk factors associated with non-persistent PIRA. We then matched persistent PIRA patients with non-persistent PIRA patients in a 1:1 ratio using propensity scores, and compared their risk of reaching EDSS 6 using the Cox regression model. We re-matched patients with complete Kurtzke Functional Systems Scores to compare their risks of reaching SPMS. We included 4713 RRMS patients with PIRA, of whom around one-third experienced a post-PIRA disability improvement, over a relatively long period (median of 2.6 years to improvement). Use of high-efficacy disease-modifying therapies (DMT) at baseline [hazard ratio, 1.22; 95% confidence interval, (1.08–1.38); P = 0.0015], lower baseline EDSS [hazard ratio, 0.73 (0.69–0.78); P < 0.0001] and younger age [per 10 years; hazard ratio, 0.84 (0.80–0.89); P < 0.0001] were associated with non-persistent PIRA. Patients with non-persistent PIRA had a hazard ratio of 0.19 [95% confidence interval, (0.15–0.25); P < 0.0001] for reaching EDSS 6 and 0.18 [(0.11–0.29); P < 0.0001] for reaching SPMS compared to patients with persistent PIRA. PIRA events slowly regress in one-third of patients. Patients with persistent PIRA had a substantially higher risk of reaching EDSS 6 and SPMS than those with non-persistent PIRA. Younger age, lower baseline EDSS, and use of high-efficacy DMT during PIRA events were associated with PIRA regression.
- Open Access
- 25 February 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (4) , 842-850
Longitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis
Background: Cognitive impairment is one of the most common and debilitating symptoms of relapsing–remitting multiple sclerosis (RRMS). Digital cognitive biomarkers require less time and resources and are rapidly gaining popularity in clinical settings. We examined the longitudinal trajectory of the iPad‐based Processing Speed Test (PST) and predictors of PST scores.Methods: We prospectively enrolled RRMS patients between 2017 and 2021 across six Australian MS centres. Longitudinal data was analysed with mixed effect modelling and latent class mixed models. We then examined whether latent class group membership predicted confirmed decrease in correct PST responses.Results: We recruited a total of 1093 participants, of which 724 had complete baseline data with a median follow up duration of 2 years. At a population level, PST trajectory was stable. A small practice effect was present up to the 4th visit. Age, baseline disability, T2 lesion volume, male sex and depression were associated with lower correct PST responses, whilst years of education and full/part‐time employment were associated with more correct PST responses.We identified four latent class trajectories of PST. The worst latent class was typified by low baseline PST and lack of a practice effect. Being in the worst latent class was associated with a greater hazard of time to sustained 5% decrease in PST (HR 2.84, 95% CI 1.16–6.94, p = 0.02).Conclusion: Worse baseline cognitive performance and lack of a practice effect predicted future cognitive decline in RRMS.
- 25 February 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (4) , 842-850
Open AccessLongitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis
Background: Cognitive impairment is one of the most common and debilitating symptoms of relapsing–remitting multiple sclerosis (RRMS). Digital cognitive biomarkers require less time and resources and are rapidly gaining popularity in clinical settings. We examined the longitudinal trajectory of the iPad‐based Processing Speed Test (PST) and predictors of PST scores.Methods: We prospectively enrolled RRMS patients between 2017 and 2021 across six Australian MS centres. Longitudinal data was analysed with mixed effect modelling and latent class mixed models. We then examined whether latent class group membership predicted confirmed decrease in correct PST responses.Results: We recruited a total of 1093 participants, of which 724 had complete baseline data with a median follow up duration of 2 years. At a population level, PST trajectory was stable. A small practice effect was present up to the 4th visit. Age, baseline disability, T2 lesion volume, male sex and depression were associated with lower correct PST responses, whilst years of education and full/part‐time employment were associated with more correct PST responses.We identified four latent class trajectories of PST. The worst latent class was typified by low baseline PST and lack of a practice effect. Being in the worst latent class was associated with a greater hazard of time to sustained 5% decrease in PST (HR 2.84, 95% CI 1.16–6.94, p = 0.02).Conclusion: Worse baseline cognitive performance and lack of a practice effect predicted future cognitive decline in RRMS.
- Open Access
- 25 February 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (4) , e210247
Association of Year-to-Year Lipid Variability With Risk of Cognitive Decline and Dementia in Community-Dwelling Older Adults
Lipid metabolism in older adults is affected by various factors including biological aging, functional decline, reduced physiologic reserve, and nutrient intake. The dysregulation of lipid metabolism could adversely affect brain health. This study investigated the association between year-to-year intraindividual lipid variability and subsequent risk of cognitive decline and dementia in community-dwelling older adults. ASPirin in Reducing Events in the Elderly (ASPREE) was a randomized trial of aspirin, involving 19,114 participants aged 65 years and older from Australia and the United States who were free of dementia and major cognitive impairment. ASPREE-eXTension is the post-trial observational follow-up of participants, currently to a maximum of 11 years. This post hoc analysis included participants who had lipid levels measured at baseline and in years 1, 2, and 3. Year-to-year variability in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and triglycerides over the first 3 years was quantified using variability independent of the mean. Individuals who initiated or discontinued lipid-lowering therapy during this period were excluded. Multivariable Cox proportional hazards regression was used to analyze associations with incident dementia, adjudicated by expert panels, and cognitive impairment with no dementia (CIND) confirmed by a battery of cognitive tests, occurring after year 3. A linear mixed model was used for assessing the association with changes in 4 cognitive function domains, including global, memory, processing speed, verbal fluency, and a composite score from baseline to the end of follow-up. The analysis included 9,846 individuals (median [interquartile range] age: 73.9 [71.7-77.3] years, 54.9% female). 509 incident dementia and 1,760 CIND events were recorded over a median follow-up of 5.8 and 5.4 years after variability assessment. The hazard ratios (95% CI) comparing the highest and lowest quartiles of TC and LDL-c variability were 1.60 (1.23-2.08) and 1.48 (1.15-1.91) for dementia and 1.23 (1.08-1.41) and 1.27 (1.11-1.46) for CIND. Higher TC and LDL-c variability was also associated with a faster decline in global cognition, episodic memory, psychomotor speed, and the composite score (all p < 0.001). No strong evidence was found for an association of HDL-c and triglyceride variability with dementia and cognitive change. Tracking variability of TC and LDL-c may serve as a novel biomarker of incident dementia and cognitive decline in older adults.
- 25 February 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (4) , e210247
Open AccessAssociation of Year-to-Year Lipid Variability With Risk of Cognitive Decline and Dementia in Community-Dwelling Older Adults
Lipid metabolism in older adults is affected by various factors including biological aging, functional decline, reduced physiologic reserve, and nutrient intake. The dysregulation of lipid metabolism could adversely affect brain health. This study investigated the association between year-to-year intraindividual lipid variability and subsequent risk of cognitive decline and dementia in community-dwelling older adults. ASPirin in Reducing Events in the Elderly (ASPREE) was a randomized trial of aspirin, involving 19,114 participants aged 65 years and older from Australia and the United States who were free of dementia and major cognitive impairment. ASPREE-eXTension is the post-trial observational follow-up of participants, currently to a maximum of 11 years. This post hoc analysis included participants who had lipid levels measured at baseline and in years 1, 2, and 3. Year-to-year variability in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and triglycerides over the first 3 years was quantified using variability independent of the mean. Individuals who initiated or discontinued lipid-lowering therapy during this period were excluded. Multivariable Cox proportional hazards regression was used to analyze associations with incident dementia, adjudicated by expert panels, and cognitive impairment with no dementia (CIND) confirmed by a battery of cognitive tests, occurring after year 3. A linear mixed model was used for assessing the association with changes in 4 cognitive function domains, including global, memory, processing speed, verbal fluency, and a composite score from baseline to the end of follow-up. The analysis included 9,846 individuals (median [interquartile range] age: 73.9 [71.7-77.3] years, 54.9% female). 509 incident dementia and 1,760 CIND events were recorded over a median follow-up of 5.8 and 5.4 years after variability assessment. The hazard ratios (95% CI) comparing the highest and lowest quartiles of TC and LDL-c variability were 1.60 (1.23-2.08) and 1.48 (1.15-1.91) for dementia and 1.23 (1.08-1.41) and 1.27 (1.11-1.46) for CIND. Higher TC and LDL-c variability was also associated with a faster decline in global cognition, episodic memory, psychomotor speed, and the composite score (all p < 0.001). No strong evidence was found for an association of HDL-c and triglyceride variability with dementia and cognitive change. Tracking variability of TC and LDL-c may serve as a novel biomarker of incident dementia and cognitive decline in older adults.